23 Jul, 2026
According to Straits Research the global automated and closed cell therapy processing systems market size was valued at $1.64 billion in 2025 and is estimated to reach $7.61 billion by 2034 growing at a CAGR of 18.62% during the forecast period.
The automated and closed cell therapy processing systems market is gaining strong momentum as the demand for scalable, standardized, and contamination-free manufacturing solutions for advanced therapies accelerates. A key driver stimulating market expansion is the rising global adoption of cell-based therapeutics, such as CAR-T, stem-cell, and gene-modified treatments, which require high precision, GMP-compliant processing platforms. As healthcare systems increasingly shift toward personalized and regenerative medicine, manufacturers are prioritizing automated, closed systems to improve consistency, reduce manual handling errors, and enable faster transition from clinical development to commercial production. This growing therapeutic pipeline is prompting biopharmaceutical companies and CDMOs to adopt integrated processing technologies capable of supporting reliable, high-throughput workflows.
However, the market faces a notable restraint in the form of high capital investment. Automated and fully closed cell therapy systems involve substantial upfront costs related to equipment procurement, facility integration, consumables, and maintenance. These financial barriers are challenging for smaller biotech firms and research institutes operating with limited budgets, slowing early-stage adoption.
Despite these constraints, a major opportunity lies in the expanding focus on allogeneic, off-the-shelf cell therapies. As these products move closer to commercialization, demand for large-scale, standardized bioprocessing solutions is rising rapidly. Automated closed systems offer an ideal pathway for industrialized manufacturing, providing the scalability, reproducibility, and regulatory compliance needed to support high-volume production. This shift toward allogeneic platforms is expected to unlock substantial growth potential for technology developers worldwide.
A key factor supporting North America’s leading share is the dense network of clinical trial pipelines and GMP‑certified contract manufacturing organizations (CMOs/CDMOs). This concentration enables rapid scaling from research to commercial production, driving high demand for automated, closed-cell therapy processing systems.
The U.S. automated and closed cell therapy processing systems market benefits uniquely from a concentrated ecosystem of more than 70 GMP-certified cell and gene therapy CDMO facilities, robust biotech hubs such as Massachusetts, California, and North Carolina, which create high demand for automated, closed cell processing platforms to support scalable, compliant manufacturing.
sales@straitsresearch.com